Myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) are the most 
common disorders of neuromuscular transmission in clinical practice. Disorders 
of the neuromuscular junction (NMJ) are characterized by fluctuating and 
fatigable weakness and include autoimmune, toxic, and genetic conditions. Adults 
with NMJ disorders are most often antibody mediated, with MG being the most 
common, having a prevalence of approximately 1 in 10,000, and with women being 
affected about twice as often as men. This article focuses on advances in 
management of autoimmune MG and LEMS.